Pillstats
Rx only · Injection, Solution · Intravenous

Furosemide

Furosemide

12 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US31 NDCs
12 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCC03CA01
RxCUI (US)4603
US makers12 labelers
Packages39
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 11 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$0.108$0.216$0.324$0.432Jul 2025Mar 2026Jul 2026
$0.351
Latest avg · Jul 22, 2026
+57%
Since Jul 23, 2025
12
Active US suppliers
33%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

3.1K6.2K9.3K12K2025 Q12025 Q22025 Q32025 Q42026 Q1
7.4K
Rx · 2026 Q1
62K
Units dispensed
-31%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it12 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Lifestar Pharma LLCunknown7SUPPLYING
Baxter Healthcare Corporationunknown6SUPPLYING
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.unknown5SUPPLYING
Medical Purchasing Solutions, LLCunknown5SUPPLYING
Devatis, Inc.unknown3SUPPLYING
Camber Pharmaceuticals, Inc.unknown3SUPPLYING
NorthStar Rx LLCunknown3SUPPLYING
ProPharma Distributionunknown2SUPPLYING
Henry Schein Inc.unknown2SUPPLYING
Cardinal Health 107, LLCunknown1SUPPLYING
Civica, Inc.unknown1SUPPLYING
REMEDYREPACK INC.repackager1SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Apr 7, 2020
    SHORTAGEDrug shortage: Furosemide Injection (Baxter Healthcare)

    Furosemide Injection — reported in shortage by Baxter Healthcare. Therapeutic category: Cardiovascular.

  • Apr 7, 2020
    SHORTAGEDrug shortage: Furosemide Injection (Avet Pharmaceuticals, Inc.)

    Furosemide Injection — reported in shortage by Avet Pharmaceuticals, Inc.. Therapeutic category: Cardiovascular.